Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? Ther Adv Med Oncol 2018;10:1758835918788310: Knowing PD-L1 Status is Not Enough: Applying a Molecular Subtype Approach to Bladder Cancer is Also Needed

Publication date: Available online 24 September 2018Source: European UrologyAuthor(s): Pontus Eriksson, Gottfrid Sjödahl, Fredrik Liedberg
Source: European Urology - Category: Urology & Nephrology Source Type: research